Post by
DeathXray33 on Sep 20, 2024 8:20am
Smaller Deals
Big Drugmakers Are Clinching Smaller Deals J&J, Merck and others are focusing on targets costing $5 billion or less, curtailing pricier acquisitions to help smooth regulators approval Aug. 12, 2024 5:30 am ET Merck has made four small acquisitions this year to diversify and deepen the companys drug pipeline. For years the worlds biggest drugmakers paid up for deals. Now they are writing much smaller checks. After shelling out tens of billions of dollars for single biotech companies, pharmaceutical giants such as AbbVie ABBV , AstraZeneca and Merck & Co. have shifted to smaller targets costing $5 billion or less. Many of the companies getting taken out are private. ------------------------------------------------ https://www.wsj.com/health/pharma/big-drugmakers-are-clinching-smaller-deals-0c039593?mod=pharma_more_article_pos12
Comment by
TimboBaggins on Sep 20, 2024 10:03am
5 Billion sounds ok to me
Comment by
Legit62 on Sep 20, 2024 10:19am
that sounds like a $20 a share buy out which im in favor of
Comment by
chry200030 on Sep 20, 2024 12:49pm
The stock will move when it's ready. One can be pretty confident that TLT will not stay at .18 much longer, whether it's next week or in 6 months. This is a Super buying opportunity for those who are patient.
Comment by
CAinPlap on Sep 20, 2024 2:49pm
It will move when management can show they can say we have rather than we hope or intend to.